Results of Clinical Study

RNS Number : 4142A

Tristel PLC

30 March 2012

 



TRISTEL plc

Results of Clinical Study

Tristel plc ("Tristel"), the manufacturer of infection control, contamination control and hygiene products, announces that at the 11th Congress for German Hospital Hygiene held in Berlin in late March, the results of a clinical study of the Tristel Wipes System were presented by Mr Brandon Hitchcock FRACS, Consultant Ear, Nose and Throat (ENT) surgeon at Tauranga Hospital, New Zealand.

In a randomised, single-blind comparison of the effectiveness of the high-level disinfectants Tristel Wipes, Cidex OPA (Johnson & Johnson) and Perasafe (Du Pont) for use with flexible nasendoscopes, the study, which involved 195 patients, concluded that none of the disinfectant agents proved harmful to patients.

However, in terms of ease of use and user safety, the Tristel Wipes were statistically superior to the other two disinfection methods, using certain well-recognised scoring measures. Furthermore, the Tristel Wipes System achieved the fastest turnaround time for the instrument disinfected (2.7 minutes versus 27.4 minutes for Cidex OPA) and eliminated any requirement for capital expenditure, making its use superior as measured by the economic cost end-point.

The Tristel Wipes System is unique.  It uses the Company's patented chlorine dioxide chemistry and is designed specifically for the decontamination of heat-sensitive, non-lumened instruments.  The system comprises a pre-clean wipe to remove surface soiling, a sporicidal wipe that kills harmful organisms within 30 seconds, and a rinse wipe.

Tristel CEO, Paul Swinney, commented: "This is the second in-use clinical study that has demonstrated the superiority of a Tristel instrument disinfectant (in this case the Wipes System) over other, longer-established methods. When it comes to instrument disinfection, there is in fact very little published data generated from the actual use of products in the clinical setting. The findings of these two studies involving the innovative products Tristel have developed for ENT, urology and cardiology, help explain the 55% growth in their sales that we achieved in our first half."

For further information please contact:

Tristel plc
Paul Swinney, Chief Executive Officer	Tel: [phone]
Liz Dixon, Finance Director
Walbrook PR Ltd
Paul McManus	Tel: [phone] or [e-mail]
Fiona Henson	Tel: [phone] or [e-mail]
finnCap
Geoff Nash / Charlotte Stranner (Corporate Finance)	Tel: [phone]
Simon Starr (Corporate Broking)

 

END

 

 

NRADBGDXGDDBGDC